Share Name |
Share Symbol |
Market |
Type |
Share ISIN |
Share Description |
4d Pharma Plc |
LSE:DDDD |
London |
Ordinary Share |
GB00BJL5BR07 |
ORD 0.25P |
|
Price Change |
% Change |
Share Price |
Bid Price |
Offer Price |
High Price |
Low Price |
Open Price |
Shares Traded |
Last Trade |
|
-0.50 |
-0.39% |
128.50 |
127.50 |
128.50 |
132.00 |
126.00 |
132.00 |
2,053,687 |
16:35:08 |
Industry Sector |
Turnover (m) |
Profit (m) |
EPS - Basic |
PE Ratio |
Market Cap (m) |
Pharmaceuticals & Biotechnology |
0.0 |
-29.4 |
-36.8 |
- |
169 |
4d Pharma Share Discussion Threads

Showing 19151 to 19174 of 19175 messages
Date | Subject | Author | Discuss |
---|
02/3/2021 19:10 | Txp, I suspect a lot of news is coincidentally going to arrive around the time of the listings, they will want to keep the LOAC shareholders happy. |  devonlad | |
02/3/2021 18:42 | Everything being set up for a big launch onto Nasdaq with lots of exciting, current news flow that will appeal hugely to the American market. |  thepaddedcell | |
02/3/2021 16:54 | hTTps://twitter.com/BlogShrey/status/1366722255670169612
To summarise, #DDDD / $LBPS is at the cutting edge of research into microbiome treatments for neurodegeneration and Parkinson's.
This is one of many 'shots on goal'.
It accomplishes a social need.
The market is worth billions.
4d Pharma leads.
Let's see what happens. |  thefartingcommie | |
02/3/2021 16:43 | Stig you're famous lol |  ozzywalker | |
02/3/2021 14:34 | If you want to read it
hTtps://finance.yahoo.com/finance/news/portage-announces-filing-third-quarter-130000554.html?guccounter=1&guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&guce_referrer_sig=AQAAAEevl773z7Z6Sodur6j3sHF3ICdEFKB9g-WyREBgXL_thECcgvCONICX9tB6bsmjdUKOrnNiY574eZPLTpR9jV2hKfvaGMrO2Puj1Ex1-3eJl2m8AwOy7XxmP-GTCqnUHNXVP7dDPA-9f6S88ldSObFTApN4ypHHRR48bWTmC22H
Or the form
hTtps://seekingalpha.com/filing/5390995 |  thresholdbypass | |
02/3/2021 14:22 | PRTG Portage have filed a $200m shelf offering
Sort of ambition we need to show |  the stigologist | |
02/3/2021 14:03 | Great spot Devon.Great research with a touch of class. |  vanduke | |
02/3/2021 13:56 | Thanks Devonlad, great spot, let the fun(ding) begin ! |  thresholdbypass | |
02/3/2021 13:39 | Devonlad was a good spot. Well done. |  frrinvest | |
02/3/2021 13:26 | Clear out the weak, onwards with the strong. |  royalalbert | |
02/3/2021 12:58 | Saves a lot of time and money as well. If this is the case, there could potentially be other collaborations with other pharmas and MRx0518. The latest sec filing and other presentations really purport the case for a fast track of MRx0518 and Merk are the leader in getting fast tracks through the FDA, just a thought.
Yes, my thoughts exactly, go big! |  devonlad | |
02/3/2021 12:45 | Devonlad
Good spot, I had expected it to be a Phase I/II but clearly given the amount of prior work from 3 other trials of MRx0518 as monotherapy and in combination the relevant regulatory authorities have deemed the Phase I to be unnecessary. That's a very important acceleration to the process of expediting approvals and commercialisation.
Total number of patients dosed with MRx0518 is over 100 now so that may be deemed a large enough sample size to have given this dispensation but it does seem unusual and indicative of the very good safety profile of this class of drug.
The original RNS did not mention the Phase of trial.
hTtps://investegate.co.uk/4d-pharma-plc--dddd-/rns/oncology-clinical-collaboration/202102080700072333O/
and it is still not up on ClinicalTrials.Gov
htTps://www.clinicaltrials.gov/ct2/results?recrs=&cond=&term=MRx0518&cntry=&state=&city=&dist=
Suspect they are in deep discussions with multiple partners right now (extra funding would allow them to expand trials without having to rely on partners funding them which could act as needless complicating / delaying factor)
Time to GO BIG, or GO HOME and given we're moving to NASDAQ 4D are GOING BIG |  the stigologist | |
02/3/2021 12:23 | Hi All,
I'm hanging on to all of my shares for the forseeable - noticed from a construction site I am on that -
The London Borough of Camden has approved plans to build a 10-storey office and research building for US pharmaceuticals giant Merck opposite King’s Cross station.
Good for 4D I would have thought in the longer term |  jimmylufc | |
02/3/2021 12:13 | Thought this was interesting: 4D has entered into a clinical collaboration and drug supply agreement with Merck KGaA & Pfizer regarding anti-PD-L1 Bavencio®(avelumab)Trial expected to commence in 2021Phase II trial of MRx0518 + Bavencio®as first-line maintenance therapy in patients with unresectable locally advanced or metastatic urothelial carcinoma•
Second MRx0518 clinical collaboration and combination with a leading immune checkpoint inhibitor•
Trial expands MRx0518 clinical program, moving into first-line maintenance setting•
Bavencio® is the first and only checkpoint inhibitor approved by the FDA in this setting
So no p1 trial, straight into p2, anyone with better knowledge than me, does the p1 trial with Keytruda mean there is no need for one in this collaboration. That would imply no further p1 trials for other collaborations? Takes a year or so out of the equation and potential for a fast track as "Bavencio® is the first and only checkpoint inhibitor approved by the FDA in this setting" |  devonlad | |
02/3/2021 12:03 | Updated corporate presentation https://twitter.com/4dpharmaplc/status/1366719945099407361?s=21 |  oil be there | |
02/3/2021 11:35 | Get up them stairs , ye good thing ! !
just got carried away there ,back into the 130s :) |  mealiff | |
02/3/2021 11:05 | hTtps://twitter.com/Stockonomist/status/1366705709140877314?s=20 |  the stigologist | |
02/3/2021 10:47 | re...Another example of how stupid Cuck, Noob Stig is.
Copy and paste expert with no expertise...re..surviving-entity
not his finest moment I grant you.;).....still a very informative and (mostly) very well-informed contributor here...I certainly appreciate the input... |  thefartingcommie | |
02/3/2021 10:32 | Always a drop following news of fund raise through placing. Reasoning behind it is sound so nothing to worry about and no reason to sell for longer term holders. Ideal if you're on here 24/7, plenty of scope if you can time it right to make a quick $ ! Upside potential remains huge in the short, medium and longer term. |  thepaddedcell | |
02/3/2021 09:52 | Think consolidation phase is coming to a close. Time to look forward and to Nasdaq in next fortnight. |  blueblood | |
02/3/2021 09:36 | Another example of how stupid Cuck, Noob Stig is.Copy and paste expert with no expertise. |  bluebear1 | |
02/3/2021 09:31 | Https://www.lawinsider.com/dictionary/surviving-entity |  on target | |
02/3/2021 09:25 | When will people actually wake up.MMs are not making you sell you do it yourself.They offer a price and you click the mouse.They prey on weak holders or traders its how the market makes money. |  cwebb07 | |
02/3/2021 09:15 | The share has been walked down from 1.50 just last week to 1.25 thats nearly 20%. It looks like someone wants in cheap and the mms are trying slowly to bring it down to fill that order. |  glasswala | |